Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06631352

Acronym

HPD_single

Enrollment

Registered

2024-10-08

Start date

2000-01-01

Completion date

2024-05-31

Last updated

2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile Duct Cancer, Gall Bladder Cancer, Hepatectomy, Hepatopancreaticobiliary (HPB) Malignancy, Pancreatoduodenectomy

Keywords

Hepatopancreatoduodenectomy

Brief summary

1. In biliary tract malignancies, achieving a microscopically clear resection margin (R0) is considered the only treatment for a cure. 2. Hepatopancreatoduodenectomy(HPD) has been considered a surgical option for patients with extensive bile duct or gallbladder cancer to achieve an R0 resection. 3. The associated high morbidity and mortality rates have prevented HPD from becoming a standard surgical procedure worldwide. 4. Over the past few decades, the understanding of the bile duct anatomy has significantly improved, and many methods have been developed to assess liver function and future remnant liver volume. 5. We aimed to evaluate the short- and long-term outcomes of HPD and to assess risk factors associated with survival, early recurrence, and major complications to better evaluate the potential of the procedure as a standard treatment.

Interventions

OTHERHepatopancreatoduodenectomy

Pancreatoduodenectomy with liver resection

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who received hepatopancreatoduodenectomy between January 2000 and December 2023.

Exclusion criteria

* Patients who had R2 resection

Design outcomes

Primary

Measure	Time frame	Description
5-year overall survival	assessed up to 60months	the time from the date of surgery to the date of death or last follow-up.
5-year disease-free survival	assessed up to 60months	from the date of surgery to the first instance of recurrence, death, or last follow-up date.

Secondary

Measure	Time frame	Description
Post operative complications	assessed up to 30 days from the surgery	Complications occured after the HPD. For example, there are post-hepatectomy liver failure, postoperative pancreatic fistula, ileus, fluid collection, pleural effusion, and etc.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026